Wisconsin Alumni Research Foundation

The University of Tennessee Research Foundation

Other

Genentech, Inc.

Novartis Nutrition Ag

Kenneth A Kudsk

Christian Gerald Krueger

Jess Dreher Reed

Dhanansayan Shanmuganayagam

Joseph Francis Pierre

Aaron F Heneghan

Rodrigo P Feliciano

Ross G Clark

Paula M Jardieu

Lester David Michels

Tannin-containing compositions and methods of using same to enhance or maintain immune function during simplified nutrition feeding. Pharmaceutical compositions, including enteral nutrition compositions, are provided. The compositions comprise such tannins as proanthocyanidins and/or hydrolysable tannins. Administering the tannins to the gastrointestinal tract of a subject receiving simplified nutrition, such as with enteral nutrition therapy or parenteral nutrition therapy, attenuates or prevents deleterious effects on the gastrointestinal immune system that would otherwise occur with the simplified nutrition.

Tannin-containing gastrointestinal formulations and methods of use

The present invention discloses a seven amino acid peptide (7AA) of bombesin. Methods for reducing the impairment respiratory tract mucosal immunity, reducing the rate of infection of the respiratory tract by pathogenic microorganisms and reducing the atrophy or dysfunction of the GALT comprising administering an effective amount of 7AA are also provided.

Compositions and methods of use for a bombesin peptide

The present invention describes methods for reducing the impairment respiratory tract mucosal immunity associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a neuropeptide. Also described are methods for reducing the rate of infection of the respiratory tract by pathogenic microorganisms associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a neuropeptide. In addition, a method of reducing the atrophy or dysfunction of the GALT comprising administering a therapeutically effective amount of a neuropeptide is described. The specification further describes compositions for reducing or preventing the impairment of intestinal or respiratory tract mucosal immunity comprising a neuropeptide and a pharmaceutically acceptable carrier.

Methods of reducing atrophy or dysfunction of gut-associated lymphoid tissue

Reduction of impairment of respiratory tract mucosal immunity

The present invention comprises an improved jejunal feeding tube comprising semi rigid tubing attached to the distal end of a percutaneous endoscopic feeding tube. The tubing further contains equidistantly spaced bushing grips on the jejunal feeding tube for ease of placement and securing the jejunal feeding tube to the small intestine.

Jejunal feeding tube

Diagnostic methods are described for using the concentration of a cytokine present in serum or other biological fluids in order to predict the predisposition of an individual to post-trauma infectious and or inflammatory complications. Also described are diagnostic kits that are particularly suitable for use in such diagnosis.

Use of an IL-6 assay for predicting the development of post-trauma

A method for increasing the T4/T8 ratio in a human with a depressed T4/T8 ratio comprising administering insulin-like growth factor I (IGF-1) is disclosed.

Insulin-like growth factor I (IGF-1) induced improvement of depressed

Diagnostic methods are described for using the concentration of a cytokine present in serum or other biological fluids in rder to predict the predisposition of an individual to post-trauma infectious and or inflammatory complications. Also described are diagnostic kits that are particularly suitable for use in such diagnosis.

A method is disclosed for stimulating a mammal's or avian's immune response, particularly immune-compromised mammals, by administration of IGF-I, alone or in combination with growth hormone. Preferably, the IGF-I is native-sequence, mature human IGF-I.

Method of stimulating immune response

A method for stimulating the immune system by treating an individual who has been immunocompromised as a result of severe trauma, including closed head injury and infection, with human growth hormone. This treatment leads to an increase in total lymphocyte number, and in an increase in the T4/T8 ratio. The treatment represents an effective therapy for maintaining or stimulating the immunocompetence of an individual who has been immunocompromised.

Growing community of inventors

Memphis, TN, United States of America

Kenneth A Kudsk